Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Annu Rev Med ; 71: 137-148, 2020 01 27.
Artículo en Inglés | MEDLINE | ID: mdl-31986084

RESUMEN

The microbiome is an integrated part of the human body that can modulate a variety of disease processes and affect prognosis, treatment response, complications, and outcomes. The importance of allogeneic hematopoietic cell transplantation in cancer treatment has resulted in extensive investigations on the interaction between the microbiome and this treatment modality. These investigations are beginning to lead to clinical trials of microbiome-targeted interventions. Here we review some of these discoveries and describe strategies being investigated to manipulate the microbiome for favorable outcomes, such as the proper selection and timing of antibiotics, type of diet and route of administration, probiotics, prebiotics, and fecal microbiota transplantation.


Asunto(s)
Antibacterianos/uso terapéutico , Bacteriemia/microbiología , Infecciones por Clostridium/microbiología , Disbiosis/microbiología , Microbioma Gastrointestinal/fisiología , Enfermedad Injerto contra Huésped/microbiología , Trasplante de Células Madre Hematopoyéticas/métodos , Infecciones del Sistema Respiratorio/microbiología , Biodiversidad , Disbiosis/etiología , Disbiosis/terapia , Neutropenia Febril/tratamiento farmacológico , Trasplante de Microbiota Fecal , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Humanos , Microbiota/fisiología , Prebióticos , Probióticos , Trasplante Homólogo
2.
East Mediterr Health J ; 24(3): 243-253, 2018 Jun 10.
Artículo en Inglés | MEDLINE | ID: mdl-29908019

RESUMEN

BACKGROUND: The United Nations has declared the Syrian refugee crisis to be the biggest humanitarian emergency of our era. Neighbouring countries, such as Jordan, strain to meet the health needs of Syrian refugees in addition to their own citizens given limited resources. OBJECTIVES: This study aimed to determine the perspectives of Syrian refugees in Jordan, Jordanian health care providers and other stakeholders in addressing the public health issues of the refugee crisis. METHODS: Qualitative and quantitative methodologies were used to explore Syrian refugee health needs and services in camp and urban settings in Jordan. Focus group discussions and key informant interviews were used to identify needs, challenges and potential solutions to providing quality health care to refugees. By-person factor analysis divided refugee participants into 4 unique respondent types and compared priorities for interventions. RESULTS: Focus group discussions and key informant interviews revealed a many different problems. Cost, limited resources, changing policies, livelihoods and poor health literacy impeded delivery of public and clinical health services. Respondent Type 1 emphasized the importance of policy changes to improve Syrian refugee health. Type 2 highlighted access to fresh foods and recreational activities for children. For Type 3, poor quality drinking-water was the primary concern, and Type 4 believed the lack of good, free education for Syrian children exacerbated their mental health problems. CONCLUSIONS: Syrian refugees identified cost as the main barrier to health care access. Both refugees and health care providers emphasized the importance of directing more resources to chronic diseases and mental health.


Asunto(s)
Personal de Salud/psicología , Necesidades y Demandas de Servicios de Salud , Refugiados/psicología , Adulto , Femenino , Grupos Focales , Humanos , Entrevistas como Asunto , Jordania , Masculino , Siria/etnología
3.
Sci Transl Med ; 14(671): eabo3445, 2022 11 16.
Artículo en Inglés | MEDLINE | ID: mdl-36383683

RESUMEN

Not all patients with cancer and severe neutropenia develop fever, and the fecal microbiome may play a role. In a single-center study of patients undergoing hematopoietic cell transplant (n = 119), the fecal microbiome was characterized at onset of severe neutropenia. A total of 63 patients (53%) developed a subsequent fever, and their fecal microbiome displayed increased relative abundances of Akkermansia muciniphila, a species of mucin-degrading bacteria (P = 0.006, corrected for multiple comparisons). Two therapies that induce neutropenia, irradiation and melphalan, similarly expanded A. muciniphila and additionally thinned the colonic mucus layer in mice. Caloric restriction of unirradiated mice also expanded A. muciniphila and thinned the colonic mucus layer. Antibiotic treatment to eradicate A. muciniphila before caloric restriction preserved colonic mucus, whereas A. muciniphila reintroduction restored mucus thinning. Caloric restriction of unirradiated mice raised colonic luminal pH and reduced acetate, propionate, and butyrate. Culturing A. muciniphila in vitro with propionate reduced utilization of mucin as well as of fucose. Treating irradiated mice with an antibiotic targeting A. muciniphila or propionate preserved the mucus layer, suppressed translocation of flagellin, reduced inflammatory cytokines in the colon, and improved thermoregulation. These results suggest that diet, metabolites, and colonic mucus link the microbiome to neutropenic fever and may guide future microbiome-based preventive strategies.


Asunto(s)
Microbioma Gastrointestinal , Trasplante de Células Madre Hematopoyéticas , Neoplasias , Neutropenia , Ratones , Animales , Propionatos , Verrucomicrobia , Moco/metabolismo , Mucinas/metabolismo , Dieta , Neutropenia/metabolismo , Neoplasias/metabolismo
4.
Hematology ; 26(1): 393-397, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34029507

RESUMEN

Background: Obesity has been associated with increased incidence of myelodysplastic syndromes (MDS). Recently intriguing data in mouse models suggested that obesity increases survival in animals with MDS.Methods: This was a retrospective analysis using the Moffitt MDS database. Obesity was defined by using body mass index (BMI), whereby a BMI ≥ 30 was regarded as obese.Results: Among 3089 MDS patients with known BMI, 963 patients (31%) were categorized as obese. There were no differences in baseline characteristics between patients with BMI ≥ 30 and those with <30. The median OS for patients with BMI ≥ 30 was 34 months compared to 37 months for those with BMI < 30 (p 0.04). For patients with lower-risk MDS median OS was 52 months versus 57 months, respectively, (p 0.08) while for higher-risk patients median OS was 17 months for both groups. The rate of AML transformation was 36% for patients with BMI ≥ 30 compared to 32% for those with BMI < 30 (p 0.009). There was no difference in response to azacitidine. In multivariable analysis, BMI was associated with inferior OS. For patients < 45 years old, the median OS was 25 months for patients with BMI ≥ 30 compared to 116 months for those with BMI < 30 (p 0.034).Conclusions: Obesity is associated with inferior overall survival (OS) in MDS patients in less than 65 years old and lower MDS risk. Impact of obesity on the outcome of MDS is being explored in both mice and human. Here we reported the impact of obesity on OS in MDS patients. Obesity is associated with inferior OS in MDS patients particularly younger age groups and lower MDS risk.


Asunto(s)
Síndromes Mielodisplásicos/mortalidad , Obesidad/mortalidad , Adulto , Factores de Edad , Anciano , Índice de Masa Corporal , Supervivencia sin Enfermedad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Tasa de Supervivencia
5.
Clin Lymphoma Myeloma Leuk ; 21(1): e52-e56, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-33093008

RESUMEN

BACKGROUND: Cytogenetic profile is an essential parameter in myelodysplastic syndromes (MDS) risk stratification by both International Prognostic Symptom Score (IPSS) and Revised (R)-IPSS. Almost one-half of patients with MDS have normal cytogenetics by metaphase karyotype. Here we report the yield of MDS fluorescence in situ hybridization (FISH) panel detecting cytogenetic abnormalities in these patients and its impact on risk stratification. PATIENTS AND METHODS: Among patients with normal metaphase karyotype, we assessed those patients who had cytogenetic abnormalities detected by an MDS FISH panel, which included probes for del (5), del (7), del (20), trisomy 8, and del (17p). Risk stratification was calculated by both IPSS and R-IPSS. RESULTS: Of 1600 patients with MDS with normal metaphase karyotype, 53 (3%) patients had cytogenetic abnormality detected by MDS FISH panel. Integrating the MDS FISH panel cytogenetics (IPSS + FISH restaging) resulted in upstaging the score, where 53% of low-risk IPSS were upstaged to intermediate (int)-1, 56% of int-1 were upstaged to int-2, and 78% of int-2 were upstaged to high risk. Based on the R-IPSS, 61% of very low-risk patients, all low-risk patients, 92% of intermediate-risk patients, and 50% of high-risk patients with FISH abnormalities were upstaged, respectively. CONCLUSION: The yield of MDS FISH panel detecting cytogenetic abnormalities in patients with normal karyotype by G-banding is low and may not warrant ordering the panel in all patients. Among the 3% of patients with normal karyotype who had cytogenetic abnormality detected by FISH, the risk score assignment by IPSS and R-IPSS was upstaged.


Asunto(s)
Citogenética/métodos , Hibridación Fluorescente in Situ/métodos , Cariotipificación/métodos , Metafase/genética , Síndromes Mielodisplásicos/terapia , Femenino , Humanos , Masculino , Síndromes Mielodisplásicos/mortalidad , Medición de Riesgo , Factores de Riesgo , Análisis de Supervivencia
6.
BMJ Case Rep ; 13(9)2020 Sep 18.
Artículo en Inglés | MEDLINE | ID: mdl-32948529

RESUMEN

A 26-year-old woman was found to have congenital dysfibrinogenaemia after presenting to our hospital with premature rupture of the membranes and vaginal bleeding. Given the absence of clear guidelines for the management of pregnancy complicated by dysfibrinogenaemia, we followed expert consensus that exists among published works, with some modifications. This case was managed by a multidisciplinary team of obstetrics-gynaecology, haematology and paediatric haematology. Here we review how the patient presented, the investigations that led to the diagnosis and the treatment options.


Asunto(s)
Afibrinogenemia/diagnóstico , Antígenos/sangre , Rotura Prematura de Membranas Fetales/etiología , Fibrinógeno/análisis , Hemorragia Uterina/etiología , Adulto , Afibrinogenemia/sangre , Afibrinogenemia/complicaciones , Afibrinogenemia/terapia , Antígenos/inmunología , Diagnóstico Diferencial , Coagulación Intravascular Diseminada/diagnóstico , Factor VIII/administración & dosificación , Femenino , Rotura Prematura de Membranas Fetales/sangre , Rotura Prematura de Membranas Fetales/terapia , Fibrinógeno/administración & dosificación , Fibrinógeno/inmunología , Hemoglobinas/análisis , Humanos , Infusiones Intravenosas , Recuento de Leucocitos , Anamnesis , Mieloma Múltiple/diagnóstico , Tiempo de Tromboplastina Parcial , Embarazo , Tiempo de Protrombina , Tiempo de Trombina , Resultado del Tratamiento , Hemorragia Uterina/sangre , Hemorragia Uterina/terapia
7.
Front Immunol ; 8: 400, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28446909

RESUMEN

Clinical evidence is accumulating for a role of the microbiome in contributing to or modulating severity of inflammatory diseases. These studies can be organized by various organ systems involved, as well as type of study approach utilized, whether investigators compared the microbiome of cases versus controls, followed patients longitudinally, or intervened with antibiotics, prebiotics, or bacterial introduction. In this review, we summarize the clinical evidence supporting the microbiome as an important mechanism in the onset and maintenance of inflammation.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA